News

The VBCF is a proud member of the VCDI - Vienna COVID-19 Diagnostic Initiative

SARS-CoV-2, the virus causing coronavirus disease-19 (COVID-19), is spreading worldwide at a fast pace. In a concerted effort including researchers...

02 Apr'20

In a new study published in the Journal Science Advances, the Bell lab at IMBA reveals how multiple highly-conserved chromatin modifying complexes...

25 Mar'20

Valneva has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development...

24 Mar'20

Valneva today provided an update on its operations as the COVID-19 situation evolves.

11 Mar'20

A marvel of complexity, the nucleus is the command center of the cell – harboring information, codes and controlled access. But different from...

08 Mar'20

Valneva announced that the Food and Drug Administration (FDA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO^...

05 Mar'20

The 7th Ubiquitin Symposium will be held at the Vienna BioCenter on 14-15 May 2020. The organisers have put together a program that covers various...

04 Mar'20

Austrian biotech company CALYXHA Biotechnologies GmbH announces the investment received from ARAX Capital Partners that complements the previously...

03 Mar'20

Protein Phosphatase 2 (PP2A) is an enzyme that plays important roles in regulating cell proliferation and by that has been shown to be a tumor...

03 Mar'20

The Weintraub Student Award is one of the most prestigious and competitive international student awards recognizing “outstanding achievement during...

27 Feb'20

Lyme and chikungunya passed key milestones in 2019. Significant value inflection expected in 2020 including Lyme Phase 2 data and partnering in...

Vienna COVID-19 Diagnostics Initiative

Fighting SARS-CoV-2 in human blood vessel organoids

Deciphering the epigenetic interplay to safeguard embryonic stem cell identity

Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study

Valneva Provides Business Update on COVID-19 Situation

Layered Liquids – reaction chambers for gene regulation

Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; New US Military RFP Issued

7th Ubiquitin Symposium at the Vienna BioCenter

CALYXHA endeavors to develop novel approaches to tissue degenerative diseases and receives support from Austrian VC and international investors

Mechanism of inactivation of the tumor suppressor PP2A: an illusion shattered by reality

VBC PhD student Anete Romanauska wins Harold M. Weintraub Graduate Student Award

Valneva Reports Record Product Sales and Major Pipeline Progress in 2019